Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
cemiplimab
EMPOWER lung1 (PDL1>50%), 2021
  NCT03088540
RCTmNSCLC - L1 - PDL1 positivecemiplimabICCpatients with confirmed stage IIIB or IIICor stage IV squamous or non-squamous non-small-celllung cancer with PD-L1 expressed in at least 50% oftumour cells283 / 280some concern
suggested
  • suggested 43 % decrease in deaths (OS) (PE)
  • suggested 46 % decrease in progression or deaths (PFS) (PE)